Keywords
Clinical Conditions
Equipment & Techniques
Science Culture
We study whether the accumulation of neurological disability observed in patients with chronic inflammatory neurological conditions can be slowed down using next generation molecular therapies. The overarching aim is to understand the basic mechanisms that allow exogenously delivered stem cells, gene therapy vectors and/or exosomes to create an environment that preserves damaged axons or prevents neurons from dying. Such mechanisms may be harnessed and used to modulate disease states in an effort to repair and/or regenerate critical components of the nervous system. By understanding the mechanisms of intercellular (stem cell) signalling, diseases of the central nervous system (CNS) may be treated more effectively, and significant neuroprotection may be achieved with new tailored molecular therapeutics. Our previous work has led to the first-in-kind clinical trials of allogeneic somatic neural stem cells in patients with progressive MS.
Mitochondrial network (Tom20, white) in human iNSCs. Nuclei are counterstained with DAPI (blue) (photo credits; Bristena Ionescu).
